Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-Current Deffered Revenue (2020 - 2025)

Historic Non-Current Deffered Revenue for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $16.3 million.

  • Cytek Biosciences' Non-Current Deffered Revenue rose 1033.34% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year increase of 1033.34%. This contributed to the annual value of $16.1 million for FY2024, which is 638.38% up from last year.
  • Per Cytek Biosciences' latest filing, its Non-Current Deffered Revenue stood at $16.3 million for Q3 2025, which was up 1033.34% from $16.6 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Non-Current Deffered Revenue ranged from a high of $16.6 million in Q2 2025 and a low of $6.3 million during Q2 2021
  • In the last 5 years, Cytek Biosciences' Non-Current Deffered Revenue had a median value of $14.4 million in 2024 and averaged $13.0 million.
  • As far as peak fluctuations go, Cytek Biosciences' Non-Current Deffered Revenue skyrocketed by 18327.55% in 2021, and later crashed by 1239.57% in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' Non-Current Deffered Revenue stood at $9.8 million in 2021, then surged by 34.06% to $13.1 million in 2022, then grew by 15.3% to $15.1 million in 2023, then rose by 6.38% to $16.1 million in 2024, then grew by 1.35% to $16.3 million in 2025.
  • Its Non-Current Deffered Revenue was $16.3 million in Q3 2025, compared to $16.6 million in Q2 2025 and $15.7 million in Q1 2025.